Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Sildenafil: Sildénafil during 10 months (50mg daily), start 30 days after surgery
Placebo: 1 platelet during 10 months (daily), start 30 days after surgery
Study summary
This study aims to evaluate the efficacy of erectile rehabilitation with Sildenafil, in men treated with neoadjuvant proctectomy and radiotherapy for rectal cancer, in preventing long-term erectile dysfunction at 12 months post-operatively.
Eligibility
Primary outcome measure(s)
- the patient's response — 12 months postoperatively
A patient is defined as a responder by a score of at least 22 for the erectile function domain of the International Index of Erectile Function (IIEF), comprising the six IIEF questions relating to erection (Q1-Q5 and Q15).
Trial sites (14)
| Facility | City | Region | Status |
|---|---|---|---|
| Chu Amiens | Amiens | France | Recruiting |
| Hopital Beauvais | Beauvais | France | Recruiting |
| Chu Besancon | Besançon | France | Recruiting |
| Aphp Bicetre | Bicêtre | France | Recruiting |
| Chu Bordeaux | Bordeaux | France | Recruiting |
| Institut Bordeaux Colorectal | Bordeaux | France | Recruiting |
| Chu Clermont-Ferrand | Clermont-Ferrand | France | Recruiting |
| Chu Lille | Lille | France | Recruiting |
| Institut Paoli-Calmettes | Marseille | France | Recruiting |
| Institut Du Cancer Montpellier | Montpellier | France | Recruiting |
| Aphp St Antoine | Paris | France | Recruiting |
| Aphp Hegp | Paris | France | Recruiting |
| Chu Rouen | Rouen | France | Recruiting |
| Chu Tours | Tours | France | Recruiting |
On this site
📄 Viagra (sildenafil) drug profile →More University Hospital, Rouen trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06123156 on ClinicalTrials.gov ↗ ← All trials in France